184 related articles for article (PubMed ID: 3694257)
1. Muscarinic receptor binding and muscarinic receptor-mediated inhibition of adenylate cyclase in rat brain myelin.
Larocca JN; Ledeen RW; Dvorkin B; Makman MH
J Neurosci; 1987 Dec; 7(12):3869-76. PubMed ID: 3694257
[TBL] [Abstract][Full Text] [Related]
2. Multiple binding affinities of N-methylscopolamine to brain muscarinic acetylcholine receptors: differentiation from M1 and M2 receptor subtypes.
el-Fakahany EE; Ramkumar V; Lai WS
J Pharmacol Exp Ther; 1986 Aug; 238(2):554-63. PubMed ID: 3755473
[TBL] [Abstract][Full Text] [Related]
3. Irreversible and quaternary muscarinic antagonists discriminate multiple muscarinic receptor binding sites in rat brain.
Norman AB; Eubanks JH; Creese I
J Pharmacol Exp Ther; 1989 Mar; 248(3):1116-22. PubMed ID: 2703964
[TBL] [Abstract][Full Text] [Related]
4. Regional distribution of M1, M2 and non-M1, non-M2 subtypes of muscarinic binding sites in rat brain.
Ehlert FJ; Tran LP
J Pharmacol Exp Ther; 1990 Dec; 255(3):1148-57. PubMed ID: 2262898
[TBL] [Abstract][Full Text] [Related]
5. Coupling of subtypes of the muscarinic receptor to adenylate cyclase in the corpus striatum and heart.
Ehlert FJ; Delen FM; Yun SH; Friedman DJ; Self DW
J Pharmacol Exp Ther; 1989 Nov; 251(2):660-71. PubMed ID: 2810116
[TBL] [Abstract][Full Text] [Related]
6. Specificity of methoctramine in blocking muscarinic receptors which inhibit adenylate cyclase in cerebellar granule cells.
McLeskey SW; Fischofer-Hahn C; Takahashi K; Wojcik WJ
Neuropharmacology; 1990 Sep; 29(9):853-60. PubMed ID: 2293064
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of binding of muscarinic receptor antagonists in rat brain homogenates.
Lee JH; el-Fakahany EE
J Pharmacol Exp Ther; 1985 Jun; 233(3):707-14. PubMed ID: 3839264
[TBL] [Abstract][Full Text] [Related]
8. Muscarinic M2 receptors coupled to inhibition of adenylate cyclase in rat heart.
Wei JW; Wang MC
Chin J Physiol; 1990; 33(4):315-27. PubMed ID: 2129026
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of muscarinic receptors on rat pancreatic acini by using 125I-quinuclidinyl benzilate and N-[3H]-methylscopolamine].
Aoki E; Adachi H; Noguchi M; Satoh S; Ohnishi S; Honda T; Konishi J
Nihon Shokakibyo Gakkai Zasshi; 1991 Aug; 88(8):1571-8. PubMed ID: 1942611
[TBL] [Abstract][Full Text] [Related]
10. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes.
Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1986 May; 237(2):411-8. PubMed ID: 3754580
[TBL] [Abstract][Full Text] [Related]
11. Muscarinic cholinergic receptor subtypes in the human brain. II. Quantitative autoradiographic studies.
Cortés R; Probst A; Tobler HJ; Palacios JM
Brain Res; 1986 Jan; 362(2):239-53. PubMed ID: 3753655
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cholinergic muscarinic receptors in the rabbit iris.
Honkanen RE; Abdel-Latif AA
Biochem Pharmacol; 1988 Jul; 37(13):2575-83. PubMed ID: 3291881
[TBL] [Abstract][Full Text] [Related]
13. Affinities of muscarinic drugs for [3H]N-methylscopolamine (NMS) and [3H]oxotremorine (OXO) binding to a mixture of M1-M4 muscarinic receptors: use of NMS/OXO-M ratios to group compounds into potential agonist, partial agonist, and antagonist classes.
Sharif NA; Williams GW; DeSantis LM
Neurochem Res; 1995 Jun; 20(6):669-74. PubMed ID: 7566362
[TBL] [Abstract][Full Text] [Related]
14. Evidence of paired M2 muscarinic receptors.
Potter LT; Ballesteros LA; Bichajian LH; Ferrendelli CA; Fisher A; Hanchett HE; Zhang R
Mol Pharmacol; 1991 Feb; 39(2):211-21. PubMed ID: 1899905
[TBL] [Abstract][Full Text] [Related]
15. Autonomic interactions in the aging heart: age-associated decrease in muscarinic cholinergic receptor mediated inhibition of beta-adrenergic activation of adenylate cyclase.
Narayanan N; Tucker L
Mech Ageing Dev; 1986 May; 34(3):249-59. PubMed ID: 3014235
[TBL] [Abstract][Full Text] [Related]
16. Muscarinic receptors in canine colonic circular smooth muscle. II. Signal transduction pathways.
Zhang LB; Buxton IL
Mol Pharmacol; 1991 Dec; 40(6):952-9. PubMed ID: 1661840
[TBL] [Abstract][Full Text] [Related]
17. Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain.
Flynn DD; Mash DC
Synapse; 1993 Aug; 14(4):283-96. PubMed ID: 8248852
[TBL] [Abstract][Full Text] [Related]
18. Characterization of [3H]pirenzepine binding to muscarinic cholinergic receptors solubilized from rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1985 Jul; 234(1):37-44. PubMed ID: 3839265
[TBL] [Abstract][Full Text] [Related]
19. Rat striatal muscarinic receptors coupled to the inhibition of adenylyl cyclase activity: potent block by the selective m4 ligand muscarinic toxin 3 (MT3).
Olianas MC; Adem A; Karlsson E; Onali P
Br J Pharmacol; 1996 May; 118(2):283-8. PubMed ID: 8735628
[TBL] [Abstract][Full Text] [Related]
20. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes.
Burke RE
Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
